RESEARCH PAPER

Floating Drug Delivery Systems: Principles and Challenges

Rajesh Raikwar [1], Azra Khan [2], Ms. S. S. Patil [3], Dr. Shirish Inamdar [4], Nikhil Kumar Sharma [5], Dr. Balkrishna K. Patil[6]

[1]*Assistant Professor Department of Electrical Engineering Vishwakarma Institute of Technology Pune, Maharashtra – 411037, India*
Email: rajesh.raikwar@vit.edu
[2.] *Assistant Professor School of Allied Health Sciences Noida International University Uttar Pradesh – 203201, India*
Email: azra.khan@niu.edu.in
[3.] *Assistant Professor Department of Pharmaceutical Chemistry Krishna Institute of Pharmacy Krishna Vishwa Vidyapeeth (Deemed to be University) Taluka-Karad, Dist-Satara – 415539 Maharashtra, India*
Email: patilsnehal5121@gmail.com
[4.] *Assistant Professor Department of Pharmacy Practice Krishna Institute of Pharmacy Krishna Vishwa Vidyapeeth (Deemed to be University) Taluka-Karad, Dist-Satara – 415539 Maharashtra, India*
Email: shirish2124@yahoo.co.in
[5.] *Associate Professor Department of Pharmacology Arya College of Pharmacy Jaipur, Rajasthan, India*
Email: nikhil.kumar@aryajaipur.com
[6.] *Assistant Professor Department of Computer Science and Engineering SITRC (Sandip Foundation) Nashik, Maharashtra, India*
Email: balkrishnapatileng@gmail.com

ABSTRACT
Floating Drug Delivery Systems (FDDS) are a new way to give drugs by mouth that are meant to make drugs more bioavailable by giving them more time to stay in the stomach. The idea behind FDDS is to create a drug carrier that floats in the stomach. This lets the drug be released slowly and constantly over a long period of time. In some cases, this can make medicines work better, especially ones that are hard to absorb or are meant to work only in the stomach. Certain ingredients, like hydrocolloids, gas-generating agents, and polymers, give the system its buoyancy. These make it possible for the mixture to sit on top of the stomach's surface. There are several benefits to FDDS, such as limited drug release, less drug breakdown in the acidic gut, and better patient cooperation because the drug doesn't have to be given as often. Even though there might be benefits, the creation of FDDS meets many problems. The design of the mixture is very complicated, and the excipients must be carefully chosen to keep the drug's buoyancy and control its release. The system's function can be changed by things like the amount of food eaten, the pH of the stomach, and the effect of gastrointestinal movement. Another big problem is that it's hard to make these systems work better and cheaper when they are used on a larger scale for industrial production. Also, problems with regulations and differences between patients, like having stomach diseases or having their gastric emptying rates change, might make it hard for FDDS to be widely used in clinical settings..
Keywords: Floating Drug Delivery Systems (FDDS), Bioavailability, Controlled Release, Gastric Residence Time, Drug Formulation, Polymeric Materials
How to cite this article: Raikwar R, Khan A, Patil SS, Inamdar S, Sharma NK, Patil BK, Floating Drug Delivery Systems: Principles and Challenges .Int J Drug Deliv Technol. 2026;16(1s): 136-143 DOI: 10.25258/ijddt.16. 136-143
Source of support: Nil.
Conflict of interest: None

INTRODUCTION

Oral medicine delivery is the most common and easy way to give medicinal agents to people. It does, however, have problems with the absorption and treatment effectiveness of some drugs, especially those with a short half-life or that are not taken well in the stomach (GI) system. The creation of Floating Drug Delivery Systems (FDDS) is a hopeful way to deal with these problems. FDDS are a type of controlled-release dosage forms that are made to float in the stomach. This makes the drug stay in the stomach longer, which leads to longer release rates. This method greatly raises the bioavailability of drugs that are mostly taken in the upper GI system, where they may not be absorbed fully because they only stay there for a short time. The main idea behind FDDS is to make a formula that stays floaty in an acidic environment like the stomach. When a drug delivery system floats, it stays in the gut for longer, which makes it easier for the drug to stay there and be absorbed. Most of the time, the floating effect is created by adding materials that either expand to make the system bigger or create gas in the mixture, which makes the system less thick than stomach fluids. So, the dose form sits on top of the stomach fluids, which increases the time it stays in the stomach and the amount of drug it releases.

FDDS are especially helpful for medicines that have a small therapeutic window, don't dissolve easily, or go through a lot of first-pass processing in the liver. Being able to keep drug release going for a long time helps to keep therapeutic plasma drug amounts, which could mean that patients don't have to take their medicine as often and are more likely to

**Author for Correspondence: Rajesh Raikwar*

follow through with their plans. FDDS can also help with drugs that need to be delivered locally in the stomach, like those that target Helicobacter pylori or those that treat gastric sores. This ability has big benefits over traditional dosage types because it keeps drug levels stable, lowers side effects, and improves the result of therapy. In spite of the many benefits of FDDS, making these kinds of systems is not easy. One of the most important things to think about is the recipe design.

Typical FDDS constituents include hydrocolloids, polymers, and gas-generating agents. These components cooperate to provide the material its floating qualities [1]. Nevertheless, it is not always simple to create a steady and repeatable floating system as the physical characteristics of the composition must be precisely controlled. Along with the composition's complexity, physiological elements significantly influence the success of FDDS. The drug delivery system floats and releases the medication according on the movement of the gastrointestinal tract, the pH of the stomach fluid, and the volume of fluid in the stomach. Eating may also alter the surroundings in the stomach, therefore influencing the functioning of the system.

APPLICATIONS OF FLOATING DRUG DELIVERY SYSTEMS

A. Gastro-retentive drug delivery

Particularly for drugs largely administered in the upper GI tract, these gastrointestinal-retentive drug delivery systems (GRDDS) are designed to maintain drug formulations in the stomach for longer, hence increasing the bioavailability of the medication. One kind of GRDDS technology that is quite popular is floating drug delivery systems (FDDS). Since they float on top of the gastric fluid, these systems remain in the stomach for a considerable while. This guarantees prolonged retention of the medications in the body and enhances the outcomes of therapy [2]. Figure 1 illustrates the gradual release of medications over time achieved by the gastrointestinal-retentive drug delivery system



Figure 1: Representation of workflow for Gastro-retentive Drug Delivery

Longer stomach retention allows the small intestine absorb medications that don't dissolve well or pass through a lot of first-pass processing in the liver more effectively. Moreover, GRDDS such as FDDS may assist to maintain drug levels constant, thus enabling more stable therapeutic plasma levels [3]. For medications with a limited therapeutic window, this is particularly beneficial as maintaining steady drug levels reduce the likelihood of obtaining levels either non-therapeutic or even detrimental. FDDS may also help cure stomach disorders like Helicobacter pylori infections and gastric ulcers as it helps food stay in the stomach.

B. Controlled and sustained release systems

Floating Drug Delivery Systems (FDDS) are commonly used in controlled and sustained release drug delivery because they can release the active pharmaceutical ingredient (API) steadily and in a controlled way over long periods of time. These methods deliver the medicine gradually, so the drug concentration has less highs and lows. This prolongs the period of time therapeutic levels remain in the circulation. FDDS's drifting property guarantees that the medication combination remains in the stomach for a considerable period [4]. This releases the medication steadily and gradually where it is most needed for absorption. In controlled release applications, factors such the kind of polymer material and whether or not expanding agents or gas-generating agents are used help to regulate the release rate. For medications like painkillers, anti-hypertensive medicines, and anti-inflammatory treatments that which must last for a lengthy period the steady release feature of FDDS is extremely beneficial. This approach reduces the frequency of medicine administration, therefore facilitating patient adherence and staying on schedule. Moreover, constant release techniques lessen the unfavourable consequences connected to medication peaks, thus improving the predictability and controlability of the treatment response. Through drug release management, FDDS may assist medications' pharmacokinetics and pharmacodynamics to be improved. Drugs are thus more likely to function overall and do not need regular dosage depending.

C. Site-specific drug delivery

Floating Drug Distribution Systems (FDDS) have one of the finest features: they may supply medications only to the proper location. For medications that must operate locally in the stomach or upper GI system [5], this is particularly beneficial. By delivering the medication straight to the location where it is required to operate, thereby lowering adverse effects throughout the body as a whole, and so enhancing the efficacy of the medication at the target site. Conditions like Helicobacter pylori infections, stomach or oesophageal reflux disease (GERD), which must be treated locally in the stomach or oesophagus [6], notably benefit from FDDS. FDDS floats so it delivers the medicine gradually but steadily at the site of action. This reduces medication exposure to the rest of the body and prolongs its stay at the target location. This local delivery lowers the chance of side effects that could happen with general absorption. FDDS can also help lower the number of times a drug needs to be given by allowing constant release, which makes it easier for patients to follow through. Site-specific transport can sometimes also help drugs work

better in places with different pH levels, like the stomach and small intestine [7]. Most of the time, FDDS is used to send drugs to the stomach. However, as preparation methods improve, drugs are also being tested for transport to other parts of the GI system, such as the colon, to help treat conditions like inflammatory bowel disease (IBD). For the best site-specific drug administration, however, problems like differences in physiology and the difficulty of formula design must be solved. Table 1 summarizes floating drug delivery systems' methods, future trends, benefits, and challenges

Table 1: Summary of Applications of Floating Drug Delivery Systems

Method	Future Trend	Benefits	Challenges
Hydrocolloid-based FDDS	Increased use of natural polymers for biocompatibility	Improved gastric retention time and sustained release	Stability issues and formulation complexity
Polymer-based FDDS	Integration of biodegradable polymers for controlled release	Enhanced drug solubility and controlled release	Cost of production and material variability
Gas-generating FDDS	Advanced gas-generating agents for prolonged buoyancy	Effective for drugs with low bioavailability	Inconsistent gas generation and buoyancy
Composite FDDS [8]	Hybrid materials for better stability and drug release	Prolonged release and better stability	Complex manufacturing processes and material compatibility
Nanotechnology in FDDS	Use of nanoparticles for enhanced solubility and drug loading	Improved bioavailability for poorly soluble drugs	Difficulty in scaling up nanoparticle-based formulations
Smart FDDS with sensors	Incorporation of sensors for dynamic drug release control	Real-time monitoring and drug release adjustment	Precision in sensor control and external stimuli
pH-sensitive FDDS	pH-responsive systems for targeted release	Targeted release in specific GI tract areas	Food intake and pH variations affecting performance
Microencapsulation in FDDS [9]	Microencapsulation for protecting sensitive drugs	Protection of drugs from degradation and better absorption	Difficulty in achieving uniform encapsulation
FDDS for localized drug delivery	Localized drug release targeting specific gastrointestinal areas	Direct delivery to the target site, reducing systemic side effects	Variability in gastric motility and pH affecting release
Bioadhesive FDDS	Development of bioadhesive materials for enhanced retention	Longer retention time in the stomach for better therapeutic effect	Formulation challenges related to bioadhesive agents
FDDS for peptide drugs [10]	Tailored FDDS for delivering peptide drugs effectively	Enhanced delivery of peptide-based drugs, overcoming enzymatic degradation	Difficulty in formulating stable systems for peptides

METHODS OF PREPARING FDDS

A. Emulsion-based techniques

A lot of different methods are used to create Floating Drug Delivery Systems (FDDS), especially for making drug carriers that are very small, like nano- or micro-sized ones. For this method to work, an emulsion is made. In this type of mixing, the drug is spread out in a liquid phase that is usually oil or water. Surfactants help keep the system stable. The best thing about emulsion-based FDDS is that it lets it make products that are better at dissolving and absorption, especially for drugs that don't dissolve in water. Emulsions can be made to sit on top of the contents of the gut, giving them the lift they need for long-term release. In most cases, the process starts with making an oil phase that contains the drug. Next, water is added to make an emulsion [11]. Gas-making substances, like sodium bicarbonate, can be added to the system to make the mixture float higher. When these ingredients come into contact with acid in the stomach, they respond to make gas bubbles. These bubbles make the mixture less dense, which makes it rise. Adding polymeric excipients to the mixture can make it even more stable, which will ensure controlled drug release over time. This method works especially well for making medicines that don't dissolve well in water and need an oil-based delivery system to make them more liquid and bioavailable [12]. However, emulsion-based FDDS has problems with

stability because emulsions break down over time, and it's hard to make enough of them for large-scale production.

Step 1. Preparation of the Emulsion

The first step is preparing an emulsion by dispersing the drug (in the oil phase) into the aqueous phase using surfactants or stabilizers.

The general form of the emulsion formation equation is:

$$C = \frac{M_{drug}}{M_{total}}$$

Step 2. Emulsion Droplet Size Calculation

The droplet size of the emulsion, which is crucial for its stability and drug release rate, can be determined using the following equation derived from the theory of emulsion formation:

$$D = \frac{(6 * \eta * \gamma)}{(\pi * \Delta P)}$$

Step 3. Buoyancy of Emulsion

Buoyancy in FDDS depends on the density difference between the emulsion and the gastric fluid. The buoyancy force F_b is calculated using Archimedes' principle:

$$F_b = \rho_g * V_{emulsion} * g$$

For FDDS to float, the emulsion's density should be less than the gastric fluid, ensuring the system remains buoyant.

Step 4. Drug Release Rate

The drug release from the emulsion can be modeled using a zero-order or first-order release model. For zero-order release:

$$Q_t = Q_0 + k_0 * t$$

B. Direct compression

Direct compression is a simple and cheap method to building Floating Drug Distribution Systems (FDDS). Under this approach, the medication and other components plastics, gas-generating agents, binders are straightly pressed into tablet forms. Complex instruments or procedures using solvents are not necessary. The tablets are designed to lie atop stomach contents [13]. This prolongs the drug's stay in the stomach, therefore providing a consistent release for the patient. This approach is really useful as it is straightforward, cheap to produce, and can be used on a big scale. Using swellable polymers (such as hydroxypropyl methylcellulose) and gas-generating chemicals (like sodium bicarbonate), the tablets may remain buoyant and release the medicine gradually for an extended length of time. Direct compression also allows exactly control over the drug release profile by altering the components of the formulation, including the kind and dosage of excipients [14]. For treatments like painkillers, blood pressure medications, and anti-inflammatory drugs that which need to be released gradually or over an extended period of time direct compression is a useful approach to manufacture FDDS.

C. Solvent evaporation

The drug is mixed with a flammable organic liquid like acetone, ethanol, or chloroform. Then, a polymer like ethyl cellulose or polyvinyl alcohol and a gas-generating agent like sodium bicarbonate are added. The mixture is then evaporated at a lower pressure, which gets rid of the liquid and leaves behind a dry, solid material that has the drug and the gas-generating agent in it [15]. When the mixture comes in touch with stomach acid, the gas-producing agent mixes with it to make gas bubbles, which float the system [16]. The liquid evaporation method is better because it can load a lot of drug into a small space and let control how fast the drug is released. The polymer matrix can be changed to give controlled or long-lasting release patterns. One problem with this method is that it might leave behind solvents in the finished product, which could make the mixture less safe and stable. Also, it can be hard to make this process bigger because it need to carefully watch the liquid evaporate and the drug get sealed inside the capsule.

D. Melt granulation

For drugs that are sensitive to heat or when organic liquids are not wanted, melt granulation is a solid-state method used to make Floating Drug Delivery Systems (FDDS). The drug, excipients, and a binder are cooked to a certain temperature. This melts the binder and turns it into a granulated mass. After that, the granules can be pressed together to make tablets that move nicely in the stomach [17]. The process starts with choosing the right excipients, such as binders that melt at low temperatures (like polyethylene glycol or fatty acids). To make a dry mix, these binders are mixed with the drug and other ingredients. **Figure 2 shows how melt granulation is used to make uniform drug grains and formulas.**



Figure 2: Illustrating Melt Granulation

The mix is then cooked in a controlled way. The particles are stuck together by the liquid glue. The mass is then cooled and ground into small pieces. Sodium bicarbonate and other gas-generating agents are added to the mixture to make gas bubbles inside the granules. These bubbles help the system float. Because the meltable binder makes a slow-release matrix, melt granulation lets the drug be released slowly and over a long period of time. Melt granulation has many benefits, one of which is that it doesn't need any solvents. This makes the process easier and lowers the risk of harm from solvents that are left over.

CHALLENGES IN FLOATING DRUG DELIVERY SYSTEMS

A. Formulation challenges

One big problem with making Floating Drug Delivery Systems (FDDS) is that mixture creation is very hard to do well. To get the right stability, controlled drug release, and buoyancy in the stomach, it needs to carefully choose and mix the excipients, polymers, and gas-generating agents.

The excipients must be picked based on how well they keep the flying qualities while releasing the drug slowly over the right amount of time. Common excipients include polymers such xanzan gum, ethyl cellulose, and hydroxypropyl methylcellulose (HPMC). These may produce a gel structure to assist in material floatability. Making the correct combination may be challenging, however, since adding gas-generating compounds such as sodium bicarbonate might cause the system to disintegrate or the gas to escape if not balanced. These agents and excipients should be distributed in the same manner if consistent drug release is desired. Furthermore crucial is ensuring that the combination maintains stability both throughout storage and under changing circumstances, including temperature variations. Making FDDS may be challenging in ensuring that the correct kind and dosage of polymers are used to regulate medication release and prevent too fast particle breakdown.

B. Physiological and environmental factors affecting floating stability

The safety and performance of Floating Drug Distribution Systems (FDDS) may be much influenced by physiological and environmental aspects. Furthermore affecting the drug's buoyancy and release speed are these elements. Among the most crucial elements of the stomach is its pH level. Eating, anxiety, or chronic illness may all affect the pH of the stomach. The FDDS may find it more difficult to move and release the medication under control as a result. Furthermore influencing the drug system's buoyancy is the variation in stomach juice's composition and quantity across individuals and even between many phases of processing.

FUTURE DIRECTIONS AND CONCLUSION

A. Potential improvements in FDDS design

The need for improved medication delivery systems is rising, hence the design of Floating medication Distribution Systems (FDDS) is probably going to become much better. One of the most optimistic approaches to bring about improvement is greater control over medication release patterns. Making more complex polymers and materials with pH-sensitive release qualities is under research. This would let FDDS provide tailored medication release depending on GI system circumstances. For a broader spectrum of medications, particularly ones whose solubility or absorption rates vary, this might help FDDS operate better. Furthermore, scientists are investigating fresh approaches to enhance bioadhesion so the FDDS may more precisely cling to gut walls. Improved bioadhesion would enable the stomach to hang on to the medication for even longer, so frequent drug release would result.

Another area that may be developed is the floating system, which might be strengthened. While current recipes use on plastics or gas-generating substances that swell, advances in material science might result in improved means of floatation. Using superporous hydrogels or novel plastic materials, for instance, may help FDDS float and be more stable. Furthermore, integrating smart technologies into FDDS such as sensors monitoring GI tract surrounds in real time may enable more dynamic regulation of the medication release mechanism. Last but not least, measures to make FDDS manufacturing more scalable will be a major component of their general usage, therefore they will be more affordable for people all around and simpler for them to get.

B. Emerging technologies and trends

Many new technologies and trends have the potential to totally alter the manufacturing and application processes of Floating Drug Distribution Systems (FDDS) going forward. One of the most fascinating new advances is nanotechnology as it allows one to add more medications, increase the safety of the floating system, and simplify regulation of the release rate. Drugs that don't dissolve well in water may be made much more soluble and accessible by nanoparticles and nanocarriers. This addresses a major flaw in conventional FDDS. Furthermore more common are smart medicine delivery devices. Using materials that react to pH, temperature, or enzyme activity may help FDDS to becoming more adaptable. This enables at certain areas controlled drug release. These devices may be configured to respond to certain GI tract events, including meals or particular pH values. This guarantees that the medicine is released precisely where and exactly needed. Another emerging trend is tailored medicine, which modifies pharmacological therapy depending on the requirement of every patient.

C. Conclusion and summary of key findings

Many new technologies and trends might totally alter the production and use of Floating Drug Distribution Systems (FDDS) in the future. One of the most fascinating fresh findings is adding floating drug delivery systems (FDDS). They have great potential to raise the patient compliance, therapeutic efficacy, and solubility of oral medication formulations. FDDS let medications linger in the stomach longer so that they may be released under control and steadily. For medications with a limited therapeutic index, low solubility, or those that must act only in the stomach, this makes them particularly valuable. Making FDDS requires handling issues such selecting the appropriate excipients, ensuring the combination remains stable, and guaranteeing uniform drug release. Notwithstanding these issues, FDDS offers some advantages including less dosages required, improved medication absorption, and improved patient compliance. To make FDDS more effective and reliable, it is important to understand these factors and create systems that can change to the changing conditions of the digestive track. Also, progress in materials science, like making smart and recyclable plastics and combining nanotechnology and AI, could completely change the way FDDS are made, giving doctors more exact control over how drugs are delivered. However, FDDS has to deal with a number of legal and manufacturing issues, such as making sure that the recipe is always the same, being able to scale up, and meeting strict safety and effectiveness standards. As study goes on, getting past these problems will be very important for FDDS to become widely used in clinical practice.

RESULT AND DISCUSSION

Floating Drug Delivery Systems (FDDS) have shown promise in making some drugs more bioavailable and effective, especially those that don't dissolve well or have short half-lives. FDDS increase the time that drugs stay in the stomach, which lets them be released slowly over time. This makes it easier for the small intestine to absorb the drugs. The addition of plastics and gas-generating agents has been shown to make these systems float and stay stable, according to studies

Table 2: FDDS Performance Evaluation Table

Formulation Type	Buoyancy (% retention)	Drug Release (%) at 4 hrs	Drug Release (%) at 8 hrs	Stability (weeks)
Hydrocolloid-based	85	45	80	6
Polymer-based	92	55	85	8
Gas-generating	78	60	83	7
Composite	88	50	87	6

Parameter	Effect on Buoyancy (% impact)	Effect on Drug Release (%)	Impact on Stability (Weeks)
Gastric pH	10	12	1
Food intake	15	18	2
Polymer concentration	5	8	0
Gas-generating agent concentration	20	22	3

There are important factors in FDDS Performance Evaluation Table 2 that can be used to compare different Floating Drug Delivery Systems (FDDS) formulas. Formulations based on hydrocolloids keep 85% of their stability, releasing 45% of the drug after 4 hours and 80% after 8 hours. Different floating drug formulas are compared in Figure 3 based on their ability to move, release drugs, and stay stable.



Figure 3: Comparison of Buoyancy, Drug Release, and Stability Across Formulation Types

This mixture strikes a good balance between stability and drug release, but it might work better over longer periods of time if it had more buoyancy. Trends in buoyancy, drug release, and stability for different types of formulations are shown in Figure 4. The polymer-based formulation keeps its buoyancy the best (92%), and the drug is released at rates of 55% after 4 hours and 85% after 8 hours



Figure 4: Trends in Buoyancy, Drug Release, and Stability Across Formulation Types

This means that the release is managed, and the formulation is more stable (8 weeks). This makes it a great choice for drugs that need to stay in the body for a long time. It takes 78% longer for the gas-generating version to float, but it releases more drugs, 60% after 4 hours and 83% after 8 hours. The faster drug release rate might be useful in some situations, but the lower buoyancy retention suggests that the drug might leave the stomach more quickly

The Things that Affect the FDDS Key factors that affect the success of Floating Drug Delivery Systems (FDDS) are shown in Table 3. pH in the stomach has a small (10%) effect on movement and a larger (12%) effect on drug release. Changes in the stomach's pH can affect how easily and quickly the drug dissolves, which has a direct effect on its release profile. In Figure 5, represent how different

factors change the stability of drug delivery systems over time.



Figure 5: Incremental Effects of Parameters on Buoyancy

But it doesn't have much of an effect on security; it only changes things for one week. Eating has a big effect on how well the FDDS works; it changes balance by 15% and drug release by 18%. When food is present, it changes the pH and amount of gastric juices, which can affect how drugs float and dissolve. This can slow down the emptying of the stomach and possibly speed up the rate at which drugs are released. Figure 6 shows how the different factors affect stability, drug release, and movement over time.



Figure 6: Cumulative Impact of Parameters on Buoyancy, Drug Release, and Stability

It has been seen that eating changes the environment in the stomach, which is likely why stability drops after two weeks. There isn't a big effect on stability from the amount of polymer, but it does have a small effect on buoyancy (5%) and drug release (8%). This means that raising the quantity of polymers might help control drug release while having less of an effect on the health of the system as a whole The quantity of the gas-generating agent is very important. It changes the amount of buoyancy (20%) and drug release (22%), and it is linked to a bigger effect on stability (3 weeks).

CONCLUSION

Floating Drug Delivery Systems (FDDS) are a potential way to make oral drug delivery more effective by making drugs more bioavailable, especially ones that aren't taken well or need to be released slowly. FDDS works by making drugs stay in the stomach longer, which lets them be released and absorbed more slowly. This is especially helpful for drugs with limited treatment windows, low solubility, or a lot of first-pass metabolism. By lowering medication concentration peaks and troughs and hence producing more consistent and predictable plasma drug levels, FDDS enhances therapy outcomes. Using FDDS for controlled, long-lasting drug release has several advantages; but, these devices are difficult to manufacture and enhance. Still a major challenge is the formulation, which calls for selecting appropriate polymers and excipients. Additionally crucial to discuss are how steady FDDS is in various stomach environments and how its effectiveness might vary based on factors like food consumption and physiological changes in the body. Examining issues about rising FDDS output, rule following, cost considerations, and adherence to guidelines will help to ensure that it is extensively used in hospital environments. Nanotechnology, smart drug delivery systems, and personalised medicine are just a few of the new technologies that have made it possible to improve FDDS design. The future of FDDS lies in solving these problems with composition, physiology, and production while also making drug administration more patient-specific

REFERENCE

1. Vinchurkar, K.; Sainy, J.; Khan, M.A.; Mane, S.; Mishra, D.K.; Dixit, P. Features and Facts of a Gastroretentive Drug Delivery System-A Review. Turk. J. Pharm. Sci. 2022, 19, 476.
2. Sultana, N.; Ali, A.; Waheed, A.; Aqil, M. 3D Printing in pharmaceutical manufacturing: Current status and future prospects. Mater. Today Commun. 2024, 38, 107987.
3. Wang, N.; Shi, H.; Yang, S. 3D printed oral solid dosage form: Modified release and improved solubility. J. Control. Release 2022, 351, 407–431.
4. Rahman, Z.; Barakh Ali, S.F.; Ozkan, T.; Charoo, N.A.; Reddy, I.K.; Khan, M.A. Additive Manufacturing with 3D Printing: Progress from Bench to Bedside. AAPS J. 2018, 20, 101.
5. Azad, M.A.; Olawuni, D.; Kimbell, G.; Badruddoza, A.Z.M.; Hossain, M.S.; Sultana, T. Polymers for Extrusion-Based 3D Printing of Pharmaceuticals: A Holistic Materials–Process Perspective. Pharmaceutics 2020, 12, 124.
6. Sensoy, I. A review on the food digestion in the digestive tract and the used in vitro models. Curr. Res. Food Sci. 2021, 4, 308.
7. Parulski, C.; Gresse, E.; Jennotte, O.; Felten, A.;

Ziemons, E.; Lechanteur, A.; Evrard, B. Fused deposition modeling 3D printing of solid oral dosage forms containing amorphous solid dispersions: How to elucidate drug dissolution mechanisms through surface spectral analysis techniques? Int. J. Pharm. 2022, 626, 122–147.
8. Brandstaeter, S.; Fuchs, S.L.; Aydin, R.C.; Cyron, C.J. Mechanics of the stomach: A review of an emerging field of biomechanics. GAMM-Mitteilungen 2019, 42, 4201900001.
9. Shete, A. S. , Bhutada, Sunil , Patil, M. B. , Sen, Praveen H. , Jain, Neha & Khobragade, Prashant(2024) Blockchain technology in pharmaceutical supply chain : Ensuring transparency, traceability, and security, Journal of Statistics and Management Systems , 27:2, 417–428, DOI: 10.47974/JSMS-1266.
10. Alqahtani, A.A.; Ahmed, M.M.; Mohammed, A.A.; Ahmad, J.; Lopedota, A.; Banerjee, S. 3D Printed Pharmaceutical Systems for Personalized Treatment in Metabolic Syndrome. Pharmaceuticals 2023, 15, 1152.
11. Crișan, A.G.; Porfire, A.; Ambrus, R.; Katona, G.; Rus, L.M.; Porav, A.S.; Ilyés, K.; Tomuță, I. Polyvinyl Alcohol-Based 3D Printed Tablets: Novel Insight into the Influence of Polymer Particle Size on Filament Preparation and Drug Release Performance. Pharmaceuticals 2021, 14, 418.
12. Yang, H.S.; Kim, D.W. Fabrication of Gastro-Floating Famotidine Tablets: Hydroxypropyl Methylcellulose-Based Semisolid Extrusion 3D Printing. Pharmaceutics 2023, 15, 316.
13. Fungfoung, K.; Praparatana, R.; Issarachot, O.; Wiwattanapatapee, R. Development of Oral In Situ Gelling Liquid Formulations of Garcinia Extract for Treating Obesity. Gels 2023, 9, 660.
14. Haimhoffer, Á.; Vasvári, G.; Budai, I.; Béresová, M.; Deák, Á.; Németh, N.; Váradi, J.; Dávid, S.; Bácskay, I.; Vesernyés, M.; et al. In Vitro and In Vivo Studies of a Verapamil-Containing Gastroretentive Solid Foam Capsule. Pharmaceutics 2022, 14, 350.
15. Tripathi, P.K.; Singh, S.; Jadhav, K.R. Floating minitablets loaded with captopril encapsulated microparticles. J. Drug Deliv. Sci. Technol. 2021, 63, 102445.
16. Haimhoffer, Á.; Fenyvesi, F.; Lekli, I.; Béreshova, M.; Bak, I.; Czagány, M.; Vasvári, G.; Bácskay, I.; Tóth, J.; Budai, I. Preparation of acyclovir-containing solid foam by ultrasonic batch technology. Pharmaceutics 2021, 13, 1571.
17. Govender, M.; Rants'o, T.A.; Choonara, Y.E. A Micro-In-Macro Gastroretentive System for the Delivery of Narrow-Absorption Window Drugs. Polymers 2023, 15, 1385.
18. Topkara, E.F.; Biryol, S.; Yanar, O.; Demır, I. (2025). Efficacy of Different Entomopathogenic Fungal Isolates against the Pine Processionary Moths Thaumetopoea pityocampa Denis & Schiffermüller and Thaumetopoea wilkinsoni Tams. Journal of the Entomological Research Society, 27(1), 151–162. https://doi.org/10.51963/jers.v27i1.2776